Lexicon Pharmaceuticals, Inc. (LXRX)
| Market Cap | 847.36M +233.5% |
| Revenue (ttm) | 69.64M +123.1% |
| Net Income | -26.09M |
| EPS | -0.07 |
| Shares Out | 423.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,018,734 |
| Open | 1.690 |
| Previous Close | 1.680 |
| Day's Range | 1.640 - 2.000 |
| 52-Week Range | 0.514 - 2.000 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 4.15 (+107.5%) |
| Earnings Date | May 7, 2026 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart fail... [Read more]
Financial Performance
In 2025, Lexicon Pharmaceuticals's revenue was $49.80 million, an increase of 60.24% compared to the previous year's $31.08 million. Losses were -$50.34 million, -74.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LXRX stock is "Strong Buy." The 12-month stock price target is $4.15, which is an increase of 107.50% from the latest price.
News
Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw a sharp revenue increase from milestone payments and reduced net loss, with strong cash reserves and lower expenses. Key pipeline programs advanced toward major regulatory milestones, and financial flexibility was enhanced through a new debt facility.
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 i...
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) th...
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May...
Lexicon to present data at AAN annual meeting on Progress Phase 2b study
Lexicon (LXRX) Pharmaceuticals announced that results from its Progress Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain, DPNP, supporting the selection of pilavapadin 10 mg as th...
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analys...
Lexicon, Novo Nordisk announce initiation of LX9851 study
Lexicon (LXRX) and Novo Nordisk (NVO) announced that Novo Nordisk has initiated a Phase 1 study with LX9851, an oral non-incretin development candidate. In March 2025, Lexicon signed an exclusive
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
The company is advancing late-stage programs in HCM, type 1 diabetes, and neuropathic pain, with strong regulatory engagement and strategic partnerships. Key milestones include imminent Phase 3 data, NDA resubmission, and new obesity drug trials with Novo Nordisk.
Lexicon announces results from post hoc analysis on data of sotagliflozin
Lexicon (LXRX) Pharmaceuticals announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kid...
Lexicon price target raised to $2.30 from $2.10 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Lexicon (LXRX) to $2.30 from $2.10 and keeps a Buy rating on the shares.
Lexicon price target raised to $6 from $4 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Lexicon (LXRX) to $6 from $4 and keeps a Buy rating on the shares following the Q4 report. The firm increased its
Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025
Advanced late-stage programs in cardiometabolic and chronic pain, reduced operating expenses by $129.5M year-over-year, and strengthened cash position by over $100M. Key milestones include over 50% enrollment in SONATA-HCM, NDA resubmission for Zynquista in 2026, and pilavapadin Phase III readiness.
Lexicon reports Q4 EPS (4c), consensus (7c)
Reports Q4 revenue $5.5M, consensus $3.14M. As of December 31, 2025, Lexicon (LXRX) had $125.2M in cash, investments and restricted cash, as compared to $238.0M in cash and investments as
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 read...
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 ...
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, Mar...
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the closing of its previously announced underwritten public offering ...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering ...
Lexicon announces common stock offering, no amount given
Lexicon (LXRX) Pharmaceuticals announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock. Lexicon currently ...
Lexicon Announces Proposed Public Offering of Common Stock
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and se...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, ...
Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin
Lexicon (LXRX) Pharmaceuticals announced the successful completion of the End-of-Phase 2, EOP2, Meeting with the U.S. Food and Drug Administration, FDA, for pilavapadin in diabetic peripheral neuropat...